The medical technology company Materna Medical has completed a successful $5 million B3 funding round. The fresh capital injection is timed to support the firm through an upcoming period of clinical and commercial scaling.
InnovaHealth Partners, Wavemaker360 Health and Band of Angels led the investment round, with additional financial backing provided by the company’s existing investor network. Materna plans to use the funds to advance pre-commercial operations and prepare its primary innovations for broader market entry.
A significant portion of the capital will be allocated toward finishing the readout for the EASE pivotal clinical trial. The medical developer also intends to build out its commercial manufacturing infrastructure and expand distribution channel access for its Milli product line. These operations are designed to prepare the business for the upcoming marketplace launch of the Ellora Obstetrical System, a specialised medical device focused on improving protective outcomes in women’s pelvic health.
The company’s commercial push coincides with the activation of its first-in-class reimbursement code, a regulatory step that will help define its long-term market access strategies.
“The company continues to consistently achieve key milestones, and we are energized by the strong ongoing support from our investors as we advance toward commercialization,” said Ariella P. Golomb, MD, Chair of the Board of Directors.
The technology group aims to accelerate its launch readiness over the next twelve months by combining production scaling with targeted outreach to medical professionals.
“We are thrilled to be entering this next phase as we prepare for the Ellora launch, bringing an important innovation to women’s health,” added Tracy MacNeal, President and CEO of Materna Medical.
